InflaRx N.V.
NASDAQ:IFRX
Overview | Financials
Company Name | InflaRx N.V. |
Symbol | IFRX |
Currency | USD |
Price | 2.47 |
Market Cap | 145,441,751 |
Dividend Yield | 0% |
52-week-range | 1.165 - 2.815 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Niels C. Riedemann M.D., Ph.D. |
Website | https://www.inflarx.de |
An error occurred while fetching data.
About InflaRx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD